Cormorant Asset Management CMPS Position
Exited12-Fund ConvergenceCormorant Asset Management exited their position in COMPASS Pathways plc (CMPS) in Q3 2024, after holding the stock for 3 quarters.
The position was first reported in Q1 2024 and has been tracked across 3 quarterly 13F filings.
CMPS is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Psilocybin in 75 days (Jun 30, 2026), making the timing of Cormorant's position particularly relevant.
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Full company profile →Short Interest
5.7%
1.2 days to cover
Cormorant Asset Management CMPS Position History
Frequently Asked Questions
Does Cormorant Asset Management own CMPS?
No. Cormorant Asset Management exited their position in COMPASS Pathways plc (CMPS) in Q3 2024. They previously held the stock for 3 quarters.
How many hedge funds own CMPS?
12 specialist biotech hedge funds currently hold CMPS, including Tang Capital Management, OrbiMed Advisors, Driehaus Capital and 9 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Cormorant Asset Management first buy CMPS?
Cormorant Asset Management's position in CMPS was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Cormorant Asset Management's CMPS position increasing or decreasing?
Cormorant Asset Management completely exited their CMPS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CMPSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Cormorant Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →